Captopril improves blood pressure but not insulin action in the spontaneously-hypertensive rat (SHR)

Arthur L Swislocki, D. T. Khuu, K. Y. Fann, M. Tait

Research output: Contribution to journalArticle

Abstract

We have previously shown that SHR, like humans with essential hypertension, are insulin resistant. Captopril has been reported to improve both blood pressure and insulin action in hypertensive humans. To determine whether SHR would demonstrate this clinically-significant drug effect, 11-week old male SHR (n=7 per group) were randomly assigned to receive either captopril (50 mg/kg-day in drinking water (C)) or water (W). Animals were treated for four weeks. Data are shown as mean±SD. Weight gain was the same in the two groups while tail systolic blood pressure measured non-invasively was significantly lower (P<0.05 by 2-way ANOVA) in C-treated rats (C = 134±8; W = 177±8 mm Hg, following four weeks of treatment). Insulin action was assessed with oral glucose tolerance tests, after four weeks of treatment. Neither glucose nor insulin values were significantly different between C and W animals (by two-way ANOVA): GLUCOSE (mg/dL) INSULIN (ng/mL) TIME (min) 0 30 60 0 30 60 W 161±61 215±32 236±15 1.79±1.6 1.45±1.12 1.23±.71 C 148±34 231±49 235±53 2.28±1.8 1.6±1.6 1.34±0.84 We conclude that in SHR treated with C for 4 weeks, there was a significant reduction of blood pressure despite no effect en insulin action. This suggests that SHR may be an imperfect model of human essential hypertension.

Original languageEnglish (US)
JournalJournal of Investigative Medicine
Volume44
Issue number1
StatePublished - 1996

Fingerprint

Captopril
Blood pressure
Inbred SHR Rats
Rats
Insulin
Blood Pressure
Analysis of variance (ANOVA)
Analysis of Variance
Animals
Glucose
Glucose Tolerance Test
Drinking Water
Weight Gain
Tail
Water
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Captopril improves blood pressure but not insulin action in the spontaneously-hypertensive rat (SHR). / Swislocki, Arthur L; Khuu, D. T.; Fann, K. Y.; Tait, M.

In: Journal of Investigative Medicine, Vol. 44, No. 1, 1996.

Research output: Contribution to journalArticle

@article{99480d5e49284978b30f8c8658143f7f,
title = "Captopril improves blood pressure but not insulin action in the spontaneously-hypertensive rat (SHR)",
abstract = "We have previously shown that SHR, like humans with essential hypertension, are insulin resistant. Captopril has been reported to improve both blood pressure and insulin action in hypertensive humans. To determine whether SHR would demonstrate this clinically-significant drug effect, 11-week old male SHR (n=7 per group) were randomly assigned to receive either captopril (50 mg/kg-day in drinking water (C)) or water (W). Animals were treated for four weeks. Data are shown as mean±SD. Weight gain was the same in the two groups while tail systolic blood pressure measured non-invasively was significantly lower (P<0.05 by 2-way ANOVA) in C-treated rats (C = 134±8; W = 177±8 mm Hg, following four weeks of treatment). Insulin action was assessed with oral glucose tolerance tests, after four weeks of treatment. Neither glucose nor insulin values were significantly different between C and W animals (by two-way ANOVA): GLUCOSE (mg/dL) INSULIN (ng/mL) TIME (min) 0 30 60 0 30 60 W 161±61 215±32 236±15 1.79±1.6 1.45±1.12 1.23±.71 C 148±34 231±49 235±53 2.28±1.8 1.6±1.6 1.34±0.84 We conclude that in SHR treated with C for 4 weeks, there was a significant reduction of blood pressure despite no effect en insulin action. This suggests that SHR may be an imperfect model of human essential hypertension.",
author = "Swislocki, {Arthur L} and Khuu, {D. T.} and Fann, {K. Y.} and M. Tait",
year = "1996",
language = "English (US)",
volume = "44",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Captopril improves blood pressure but not insulin action in the spontaneously-hypertensive rat (SHR)

AU - Swislocki, Arthur L

AU - Khuu, D. T.

AU - Fann, K. Y.

AU - Tait, M.

PY - 1996

Y1 - 1996

N2 - We have previously shown that SHR, like humans with essential hypertension, are insulin resistant. Captopril has been reported to improve both blood pressure and insulin action in hypertensive humans. To determine whether SHR would demonstrate this clinically-significant drug effect, 11-week old male SHR (n=7 per group) were randomly assigned to receive either captopril (50 mg/kg-day in drinking water (C)) or water (W). Animals were treated for four weeks. Data are shown as mean±SD. Weight gain was the same in the two groups while tail systolic blood pressure measured non-invasively was significantly lower (P<0.05 by 2-way ANOVA) in C-treated rats (C = 134±8; W = 177±8 mm Hg, following four weeks of treatment). Insulin action was assessed with oral glucose tolerance tests, after four weeks of treatment. Neither glucose nor insulin values were significantly different between C and W animals (by two-way ANOVA): GLUCOSE (mg/dL) INSULIN (ng/mL) TIME (min) 0 30 60 0 30 60 W 161±61 215±32 236±15 1.79±1.6 1.45±1.12 1.23±.71 C 148±34 231±49 235±53 2.28±1.8 1.6±1.6 1.34±0.84 We conclude that in SHR treated with C for 4 weeks, there was a significant reduction of blood pressure despite no effect en insulin action. This suggests that SHR may be an imperfect model of human essential hypertension.

AB - We have previously shown that SHR, like humans with essential hypertension, are insulin resistant. Captopril has been reported to improve both blood pressure and insulin action in hypertensive humans. To determine whether SHR would demonstrate this clinically-significant drug effect, 11-week old male SHR (n=7 per group) were randomly assigned to receive either captopril (50 mg/kg-day in drinking water (C)) or water (W). Animals were treated for four weeks. Data are shown as mean±SD. Weight gain was the same in the two groups while tail systolic blood pressure measured non-invasively was significantly lower (P<0.05 by 2-way ANOVA) in C-treated rats (C = 134±8; W = 177±8 mm Hg, following four weeks of treatment). Insulin action was assessed with oral glucose tolerance tests, after four weeks of treatment. Neither glucose nor insulin values were significantly different between C and W animals (by two-way ANOVA): GLUCOSE (mg/dL) INSULIN (ng/mL) TIME (min) 0 30 60 0 30 60 W 161±61 215±32 236±15 1.79±1.6 1.45±1.12 1.23±.71 C 148±34 231±49 235±53 2.28±1.8 1.6±1.6 1.34±0.84 We conclude that in SHR treated with C for 4 weeks, there was a significant reduction of blood pressure despite no effect en insulin action. This suggests that SHR may be an imperfect model of human essential hypertension.

UR - http://www.scopus.com/inward/record.url?scp=33749553747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749553747&partnerID=8YFLogxK

M3 - Article

VL - 44

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 1

ER -